BIIB vs REGN: How Biogen and Regeneron Pharmaceuticals Compare (2026)
Last updated July 2026
Short answer
REGN is the larger of the two ($65.50B market cap): the incumbent the market prices for continued execution (11.62x forward earnings, beta 0.24). BIIB is the smaller challenger ($29.40B), priced similarly on forward earnings (11.99x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BIIB vs REGN: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BIIB | REGN | What it tells you |
|---|---|---|---|
| Market cap | $29.40B | $65.50B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.99 | 11.62 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 21.41 | 15.25 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.16 | 0.24 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 79% of range | 33% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.58 | 2.03 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BIIB and REGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Biogen (BIIB) do?
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.
BIIB vs REGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
- REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. For REGN, the clearest risk is Eylea biosimilar erosion.
BIIB or REGN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and REGN guides.
BIIB vs REGN: the full fundamentals
BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.
REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
Headline figures (approximate, MAY 2026): BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.
The bottom line: BIIB vs REGN
BIIB and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and REGN exposure against your real portfolio. It is not an investment adviser.
Build a basket around BIIB with Walnut
Use Biogen as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between BIIB and REGN?
+
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BIIB or REGN the better stock?
+
Neither is universally better. REGN is the larger incumbent; BIIB is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BIIB or REGN?
+
On forward P/E (as of July 2026), BIIB trades at 11.99x and REGN at 11.62x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BIIB and REGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BIIB vs REGN?
+
BIIB: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, and contingent value payments tied to Syfovre sales create uncertain future costs. Biotech pipelines carry binary clinical and regulatory outcomes, and a single trial failure or safety signal can move the stock sharply. The low valuation reflects genuine skepticism that new products can offset the eroding base fast enough. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BIIB or REGN; figures are approximate and dated (as of July 2026). Verify current data before investing.